Upharmacia January 2017 (Special Edition) | Page 12

Upharmacia January 2017
MARKET & COMPANIES
JANUARY 2017
I n 2017, B iofarma to I nvest
UAH 40 mio in its P roduction
Ukrainian
producer
of blood
preparations plans to invest
UAH 40 mio in its production
and to launch 15 new products
in 2017, the Chairman of
the Supervisory Board
Konstantin Efimenko of the
company said. The company
also expects increase of its
retail sales by 30% y-o-y and
growth of its exports by 50%
y-o-y. To expand its export
opportunities, Biofarma seeks
to finish formation of 25
pharmaceutical dossiers in the
European format. This year,
Biofarma is also to launch a
new plasma fractionation plant.
According to Mr. Efimenko,
in 2016, Biofarma increased
pharmacy sales by 36.6% y-o-y
to UAH 372.7 mio, while its
export enhanced 60% y-o-y.
U nipharm W ill
P resent I nterests
of B osnalijek in
U kraine
U.S. company Unipharm,
Inc. reached the agreement
with largest pharmaceutical
company in Bosnia and
Herzegovina Bosnalijek d.d. on
presentation of the company’s
interests in Ukraine. Unipharm
will manage Bosnalijek’s
product portfolio including the
12
distribution, registration, re-
registration and promotion in
Ukraine. The deal is expected to
be completed by Apr 2017.
The Director of Unipharm
representative office in Ukraine
Alexander Shalunov will lead
the RO of Bosnalijek to provide
effective integration of two
businesses.
“We are sure, that the decision
made will strengthen positions
of both companies and ensure
the development within the
difficult conditions of the
Ukrainian pharmaceutical
market,” the Unipharm
press-release said.
F armak R eceived GMP
C ertificate for P roduction
of API s in
S hostka
Production
facilities of the Ukrainian
company Farmak in Shostka
(Sumy Region) has passed
inspection on their compliance
with national and European
GMP requirements. In Dec 2015,
Farmak created a separate
manufacturing of substances
in Shostka. The manufacturing
was established as part of
expansion of production of
finished drugs and active
pharmaceutical ingredients
(API). The complex includes
manufacturing sites, quality
control laboratories and logistic
center. The staff currently
includes 86 employees.
Farmak retained a leading
position on the Ukrainian
pharmaceutical market in 2016.
U kraine to R each V oluntary
S ettlement with G ilead on
S ofosbuvir
Ukrainian
government will
sign voluntary settlement with
Gilead Sciences Inc. regarding
patent protection of Sovaldi
(sofosbuvir). Earlier, the U.S.
company sought to cancel
state registration of sofosbuvir
generic Grateziano (Pharmco),
which had been registered
before Sovaldi. In Oct 2016, Kyiv
Administrative Court refused
to cancel state registration of
Grateziano.
“During negotiations, we have
managed to find a compromise
for Gilead to renounce it’s
claims to Ukraine,” the Justice
Minister of Ukraine said. “We
will take measures to eliminate
violations of the legitimate
patent rights, while Gilead is to
provide the Ukrainian market a
discount on the drug”.
After reaching the agreement,
Gilead would not raise any
financial claims, the company’s
officials said. Within the Global
Access Program, where Ukraine
is included, the price of Sovaldi
for public procurements should
be USD 250 per package.
www.upharma-c.com